TRANSGENIC GROUP INC. [2342.T]
TOKYO, Apr 22 (Pulse News Wire) – Transgenic Group Inc. (2342.T) announced today that it has received a patent approval from the United States Patent Office for its humanized exon mouse technology related to the "Exon Humanized Mouse." The company filed an international patent application (PCT/JP2019/21,894) on May 27, 2019.
This patented technology allows for the creation of mice where exons retain human DNA sequences while introns maintain mouse DNA sequences, ensuring normal gene expression patterns quantitatively and tissue specifically. Unlike previous methods which often resulted in abnormal gene expression levels and patterns, this innovation provides a more accurate disease model for drug development and efficacy testing. Transgenic Group has successfully developed several models using this technology, including the Transthyretin (TTR) exon-humanized mouse for amyloidosis treatment research and the ACE2 exon-humanized mouse for COVID-19 studies. These models enable high-value services such as contract manufacturing, sales, and collaborative research, expanding their potential applications in preclinical trials.
The company expects this intellectual property to strengthen its competitive position in the pharmaceutical support service sector. However, there will be no impact on the consolidated performance for the fiscal year ending March 2027. Any future developments will be promptly disclosed. Transgenic Group remains committed to enhancing its value-added pharmaceutical support services moving forward.
🟢 Confidence: High AI-translated content.